Sanofi (SNY) Q3 2026 Earnings Review: Dupixent growth lifts the profit outlook
Earnings results
- EPS
Actual: €3.55 business profit per ordinary share · Matching consensus not verified.
- Revenue
Actual: €14.444B · Matching euro consensus not verified.
- Guidance raised
Sales growth: low teens vs. around 10%; business EPS: mid teens vs. slightly above sales, excluding currency.
What the company reported
Sanofi raised its full-year earnings outlook as Dupixent and new medicines drove growth, while stronger cash generation gives it more room to rebuild its pipeline.
Q3 2026 earnings recap
Sanofi raised its full-year earnings outlook as Dupixent and new medicines drove growth, while stronger cash generation gives it more room to rebuild its pipeline.
- Third-quarter sales reached €14.44 billion, up 14.3% excluding currency movements, while business profit per ordinary share, excluding specified costs, rose 19.6% to €3.55 on the same basis.
- Dupixent sales rose 34.8% to €5.7 billion excluding currency movements, making the treatment the largest contributor to growth and a major source of concentration risk.
- Full-year sales growth is now expected in the low teens rather than around 10%, with business profit growth in the mid teens rather than slightly ahead of sales, excluding currency movements.
- Vaccine sales fell 6.6% to €3.2 billion excluding currency movements because of respiratory-product delivery timing, tempering the strength in medicines.
- Nine-month free cash flow rose 28.3% to €6.99 billion, supporting investment in new medicines as management expands its collaboration with Regeneron.
- At the October 29 close, shares traded around twice trailing sales, with support near $40.5–41.10 and resistance around $43.1–43.80.
Investors should watch whether new launches and pipeline deals can sustain growth beyond Dupixent, while regulatory setbacks, pricing pressure and acquisition costs remain risks.
Financials, technicals and earnings
Charts through Oct 29, 2026.
Technical setup and risks
Dupixent and new medicines lift guidance while vaccines weaken; rebuilding the pipeline and sustaining cash generation are the next investor tests.
AI-assisted earnings research with verified issuer results. Charts use the stated completed session. Educational information; investing involves risk.